Bio Vitos Pharma AB

BIOVIT

SE0009320278

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Stockholm Other stock markets 10:38:00 28/05/2024 BST			5-day change	1st Jan Change
0.1485 ^SEK	+3.48%		-7.19%	-37.61%

02-14	Bio Vitos Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
02-14	Bio Vitos Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Hemcheck Sweden AB Receives an Additional Follow-Up Order from Its Uk Distributor

March 02, 2023 at 04:00 pm

Hemcheck Sweden AB (publ) has received another follow-up order from its UK distributor, CLS. The order concerns instruments for diagnostic use and bgs-Test and is of lower economic value.

Latest news about Bio Vitos Pharma AB

Bio Vitos Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-14	CI
Bio Vitos Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-14	CI
Bio Vitos Pharma Teams Up with KFUM Kalmar to Explore Benefits of Iron Succinate for Female Athletes	02-12	MT
KFUM Kalmar and Bio Vitos Pharma Sign Collaboration Agreement to Conduct Research Study on Succifer	02-12	CI
The European Patent Office EPO Grants Patent to Bio Vitos Pharma AB	12-20	CI
Hemcheck Sweden AB will Change its Ticker to BIOVIT from HEMC	12-06	CI
Hemcheck Sweden AB will Change its Name to Bio Vitos Pharma AB	12-06	CI
Hemcheck Sweden AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-16	CI
Hemcheck Sweden AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	30/08/23	CI
Hemcheck Sweden AB Receives A First Order from Its Distributor Astemed	15/05/23	CI
Hemcheck Sweden AB Reports Earnings Results for the First Quarter Ended March 31, 2023	09/05/23	CI
Hemcheck Sweden Receives New Follow Up Order from the Foundation for Innovative New Diagnostics	26/04/23	CI
Hemcheck Sweden AB Receives First Order from the University Hospital Charité in Berlin	05/04/23	CI
Hemcheck Sweden AB Receives First Follow Up Order from Its Finnish Distributor	13/03/23	CI
Hemcheck Sweden AB Receives an Additional Follow-Up Order from Its Uk Distributor	02/03/23	CI
Hemcheck Receives Follow Up Order from Research Program in the United States	28/02/23	CI
Hemcheck Sweden AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	14/02/23	CI
Hemcheck Sweden AB Reports Earnings Results for the Full Year Ended December 31, 2022	14/02/23	CI
YRRO Ltd agreed to acquire Hemcheck Sweden AB (OM:HEMC) in a reverse merger transaction for SEK 85.7 million.	07/02/23	CI
Hemcheck Sweden AB Receives Follow-Up Order from Eurobio Scientific	03/02/23	CI
Hemcheck Sweden AB Receives Follow-Up Order from CLS	01/02/23	CI
Hemcheck Receives First Order from Landspitali	24/01/23	CI
Hemcheck Receives a Follow Up Order from Its Spanish Distributor	23/01/23	CI
Hemcheck Receives Another Follow Up Order from Its Irish Distributor	16/01/23	CI
Hemcheck Sweden AB Extends Agreement Regarding Previously Communicated Project with Region Skåne	03/01/23	CI

Bio Vitos Pharma AB, formerly Hemcheck Sweden AB, is a Sweden-based medical technology company. The Company produces and commercializes a service for near-patient detection of hemolysis in blood samples. The concept consists of disposable tests as well as readers that can quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. The Company's, ruptured red blood cells, is a common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Its goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, the Company can contribute to increased patient safety, more efficient processes and lower costs.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
BIO VITOS PHARMA AB	-37.61%	3.98M
BIOMÉRIEUX	-6.21%	12.2B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-3.06%	8.22B
DIASORIN S.P.A.	+5.68%	5.72B
LANTHEUS HOLDINGS, INC.	+26.16%	5.42B
AUTOBIO DIAGNOSTICS CO., LTD.	-10.38%	4.09B
10X GENOMICS, INC.	-59.63%	2.7B
ANDON HEALTH CO., LTD.	+9.56%	2.63B
VITROLIFE AB	-4.26%	2.38B
MYRIAD GENETICS, INC.	+21.00%	2.1B